文献速递中毒与环境急症消化、代谢与肾脏急症

急诊科出院时纳洛酮处方趋势:2012-2019年全国分析

Trends in naloxone prescribed at emergency department discharge: A national analysis (2012-2019).
PubMed 文献 · Am J Emerg Med · 2023-01-05
一句话结论2012至2019年美国急诊出院纳洛酮处方率从0%升至0.075%(p=0.002),纳洛酮与阿片类共处方及急诊使用阿片类后出院开纳洛酮均增加。

本研究基于2012至2019年全国医院门诊医疗调查(NHAMCS)数据,回顾性分析急诊出院时纳洛酮处方趋势。主要结局为急诊就诊出院时纳洛酮处方率的变化,同时计算急诊给予纳洛酮且出院处方、出院时纳洛酮与阿片类共处方、急诊使用阿片类且出院处方纳洛酮的比例。结果显示出院纳洛酮处方率从2012年0%升至2019年0.075%(p=0.002),共处方(SR=0.76,P=0.03)及急诊使用阿片类后出院开纳洛酮(SR=0.80,p=0.02)均增加。作者认为需未来研究确认趋势并采取针对性干预增加该救命解毒剂的可及性。

要点

  • 2012至2019年急诊出院纳洛酮处方率从0%升至0.075%(p=0.002),估计总就诊250,365次。
  • 急诊给予纳洛酮且出院处方纳洛酮的比例随时间增加(PC=0.8,p=0.02)。
  • 出院时纳洛酮与阿片类共处方增加(SR=0.76,P=0.03)。
  • 急诊就诊期间使用阿片类且同次出院处方纳洛酮增加(SR=0.80,p=0.02)。
  • 作者认为需未来研究确认趋势,并采取针对性干预增加纳洛酮可及性。

适用人群与场景

  • 2012至2019年全国医院门诊医疗调查(NHAMCS)收集的急诊就诊数据,为IRB豁免的回顾性审查。

研究设计与关键结果

  • 研究类型:基于全国医院门诊医疗调查(NHAMCS)2012至2019年数据的IRB豁免回顾性审查,采用描述性统计及Spearman's Rho(SR)或Pearson相关(PR)描述趋势。
  • 主要结局:急诊出院时纳洛酮处方率从2012年占所有急诊就诊的0%升至2019年的0.075%(p=0.002),估计总就诊250,365次。
  • 急诊给予纳洛酮且出院处方纳洛酮的比例增加(PC=0.8,p=0.02)。
  • 出院时纳洛酮与阿片类共处方增加(SR=0.76,P=0.03)。
  • 急诊就诊期间使用阿片类且同次出院处方纳洛酮增加(SR=0.80,p=0.02)。

证据类型、等级与局限

  • 证据类型:基于全国调查数据的回顾性审查。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为未来应进行研究以确认这些趋势,并实施针对性干预以增加这种救命解毒剂的可及性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: While having access to naloxone is recommended for patients at risk for opioid overdose, little is known about trends in national naloxone prescribing rates in emergency departments (EDs) both for co-prescription with opioids and for patients who presented with opioid abuse or overdose. This study aims to evaluate the change in naloxone prescribing and opioid/naloxone co-prescribing at discharge using national data.

METHODS: We conducted an IRB exempt retrospective review of data collected by the National Hospital Ambulatory Medical Care Survey from 2012 to 2019. The primary outcome was trend in rate of naloxone prescribing at discharge from ED visits. We also computed the proportion of visits where naloxone was both administered in the ED and prescribed at discharge, where naloxone and opioids were co-prescribed at discharge, and where an opioid was administered during the ED visit and naloxone was prescribed at discharge. All data were summarized using descriptive statistics and Spearman's Rho (SR) or Pearson's correlation (PR) were used to describe trends.

RESULTS: There was an estimated total of 250,365 patient visits where naloxone was prescribed at discharge with an increasing rate over time (0% of all ED visits in 2012 to 0.075% in 2019, p = 0.002). There were also increases in naloxone being both administered in the ED and prescribed at discharge (PC: 0.8, p = 0.02) as well as in naloxone and opioid co-prescribing (SR: 0.76, P = 0.03). There was an increase in utilization of opioids during the ED visit and naloxone prescribing at discharge for the same visit (SR: 0.80, p = 0.02).

CONCLUSION: There are increases in naloxone prescribing at discharge, naloxone and opioid co-prescribing, and opioid utilization during the same visit where naloxone is prescribed at discharge. Future studies should be done to confirm such trends, and targeted interventions should be put into place to increase access to this life-saving antidote.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Ramdin C, Chandran K, Nelson L, et al. Trends in naloxone prescribed at emergency department discharge: A national analysis (2012-2019). Am J Emerg Med. 2023. PMID: 36638613. doi:10.1016/j.ajem.2023.01.006

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。